Breaking News, Collaborations & Alliances

Altea, KAI Enter Development Pact

Altea Therapeutics has entered into a partnership with KAI Pharmaceuticals for the preclinical and clinical development of certain KAI peptides using Altea’s PassPort Transdermal Delivery System.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Altea Therapeutics has entered into a partnership with KAI Pharmaceuticals for the preclinical and clinical development of certain KAI peptides using Altea’s PassPort Transdermal Delivery System. Altea has granted KAI an option to receive a worldwide technology license for further development and commercialization of these transdermal products. Should KAI exercise the option, it will fund all product development, manufacturing and commercialization, while Altea will receive license payments, ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters